Dominique Bellet earned a degree of pharmacy in 1973, his M.D. in 1982, and his Ph.D. in Immunology in 1985. Since 1982, he has been appointed as physician in charge of clinical laboratories in comprehensive cancer centers and is specialized in the diagnosis and follow-up of cancers using tumor markers. At the present time, he is chief of the Oncobiology Laboratory at Institut Curie-Hôpital René Huguenin (CRH), a leading comprehensive cancer in Europe. In 1987, he was appointed Professor of Immunology at University Paris Descartes. Since 1983, he has been a member of the Faculty of Harvard Medical School and the Massachusetts General Hospital.
His main scientific interest is the characterization of biomarkers and the translation of basic research findings into clinical practices and new medicines.
In translational research, his group has developed 5 tests for the diagnosis and follow-up of liver, bladder, thyroid, testis or placental cancers, for the screening of Down’s syndrome and for the diagnosis of sepsis, respectively. These tests are now used routinely by thousands of laboratories in more than 90 different countries all over the world.
He is the author of 154 scientific publications and co-inventor of 18 patents